Advertisement

Metabolic Alterations

  • Christian Delles
  • Anna F. Dominiczak
Chapter

Introduction

The prevalence of obesity is steadily increasing in Western societies, and currently about a third of the US population are obese [ 1]. Similarly, hypertension is a worldwide phenomenon that affects both developed and developing countries, and about a quarter of the world's population has elevated blood pressure [ 2]. If two highly prevalent conditions co-exist, it is very likely that many patients are affected by both. In addition to the statistical odds, there are, however, also causal relationships between metabolic disorders, obesity, and hypertension [ 3]. These pathophysiological mechanisms and their implications on patients with hypertension will be the subject of this chapter (Fig.  3.1).

Keywords

Hypertension  Metabolic syndrome  Sympathetic nervous system   Renin–angiotensin–aldosterone system  Inflammation  

References

  1. 1.
    Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303(3):235–241PubMedCrossRefGoogle Scholar
  2. 2.
    Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365(9455):217–223PubMedGoogle Scholar
  3. 3.
    Malnick SD, Knobler H (2006) The medical complications of obesity. QJM 99(9):565–579PubMedCrossRefGoogle Scholar
  4. 4.
    Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C (2004) Definition of metabolic syndrome: report of the National heart, lung, and blood institute/American heart association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 24(2):e13–e18PubMedCrossRefGoogle Scholar
  5. 5.
    Modan M, Almog S, Fuchs Z, Chetrit A, Lusky A, Halkin H (1991) Obesity, glucose intolerance, hyperinsulinemia, and response to antihypertensive drugs. Hypertension 17(4):565–573PubMedCrossRefGoogle Scholar
  6. 6.
    Garrison RJ, Kannel WB, Stokes J III, Castelli WP (1987) Incidence and precursors of hypertension in young adults: the Framingham offspring study. Prev Med 16(2):235–251PubMedCrossRefGoogle Scholar
  7. 7.
    Stevens J, Chambless LE, Tyroler HA, Rosamond W, Nieto FJ et al (2002) Associations between weight gain and incident hypertension in a bi-ethnic cohort: the atherosclerosis risk in communities study. Int J Obes Relat Metab Disord 26(1):58–64PubMedCrossRefGoogle Scholar
  8. 8.
    Huang Z, Willett WC, Manson JE, Rosner B, Stampfer MJ, Speizer FE et al (1998) Body weight, weight change, and risk for hypertension in women. Ann Intern Med 128(2):81–88PubMedCrossRefGoogle Scholar
  9. 9.
    Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B et al (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351(26):2683–2693PubMedCrossRefGoogle Scholar
  10. 10.
    Delles C, Padmanabhan S (2012) Genetics and hypertension: is it time to change my practice? Can J Cardiol 28(3):296–304PubMedCrossRefGoogle Scholar
  11. 11.
    Pausova Z, Gossard F, Gaudet D, Tremblay J, Kotchen TA, Cowley AW et al (2001) Heritability estimates of obesity measures in siblings with and without hypertension. Hypertension 38(1):41–47PubMedCrossRefGoogle Scholar
  12. 12.
    Melka MG, Bernard M, Mahboubi A, Abrahamowicz M, Paterson AD, Syme C et al (2012) Genome-wide scan for loci of adolescent obesity and their relationship with blood pressure. J Clin Endocrinol Metab 97(1):E145–E150PubMedCrossRefGoogle Scholar
  13. 13.
    Pausova Z, Syme C, Abrahamowicz M, Xiao Y, Leonard GT, Perron M et al (2009) A common variant of the FTO gene is associated with not only increased adiposity but also elevated blood pressure in French Canadians. Circ Cardiovasc Genet 2(3):260–269PubMedCrossRefGoogle Scholar
  14. 14.
    Pausova Z, Gaudet D, Gossard F, Bernard M, Kaldunski ML, Jomphe M et al (2005) Genome-wide scan for linkage to obesity-associated hypertension in French Canadians. Hypertension 46(6):1280–1285PubMedCrossRefGoogle Scholar
  15. 15.
    Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU et al (2010) Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 42(11):937–948PubMedCrossRefGoogle Scholar
  16. 16.
    Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI et al (2011) Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478(7367):103–109PubMedCrossRefGoogle Scholar
  17. 17.
    Aghamohammadzadeh R, Heagerty AM (2012) Obesity-related hypertension: epidemiology, pathophysiology, treatments, and the contribution of perivascular adipose tissue. Ann Med 44(Suppl 1):S74–S84PubMedCrossRefGoogle Scholar
  18. 18.
    Chaudhary K, Buddineni JP, Nistala R, Whaley-Connell A (2011) Resistant hypertension in the high-risk metabolic patient. Curr Diab Rep 11(1):41–46PubMedCrossRefGoogle Scholar
  19. 19.
    Muller DN, Hilgers KF, Bohlender J, Lippoldt A, Wagner J, Fischli W et al (1995) Effects of human renin in the vasculature of rats transgenic for human angiotensinogen. Hypertension 26(2):272–278PubMedCrossRefGoogle Scholar
  20. 20.
    Egan BM, Lu G, Greene EL (1999) Vascular effects of non-esterified fatty acids: implications for the cardiovascular risk factor cluster. Prostaglandins Leukot Essent Fatty Acids 60(5–6):411–420PubMedCrossRefGoogle Scholar
  21. 21.
    Ross R (1999) Atherosclerosis–an inflammatory disease. N Engl J Med 340(2):115–126PubMedCrossRefGoogle Scholar
  22. 22.
    Salgado-Somoza A, Teijeira-Fernandez E, Fernandez AL, Gonzalez-Juanatey JR, Eiras S (2010) Proteomic analysis of epicardial and subcutaneous adipose tissue reveals differences in proteins involved in oxidative stress. Am J Physiol Heart Circ Physiol 299(1):H202–H209PubMedCrossRefGoogle Scholar
  23. 23.
    Greenstein AS, Khavandi K, Withers SB, Sonoyama K, Clancy O, Jeziorska M et al (2009) Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation 119(12):1661–1670PubMedCrossRefGoogle Scholar
  24. 24.
    Sowers JR (1991) Is hypertension an insulin-resistant state? Metabolic changes associated with hypertension and antihypertensive therapy. Am Heart J 122(3 Pt 2):932–935PubMedCrossRefGoogle Scholar
  25. 25.
    Cersosimo E, DeFronzo RA (2006) Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 22(6):423–436PubMedCrossRefGoogle Scholar
  26. 26.
    Schneider MP, Delles C, Fleischmann E, Schmidt BM, John S, Schmieder RE (2003) Effect of elevated triglyceride levels on endothelium-dependent vasodilation in patients with hypercholesterolemia. Am J Cardiol 91(4):482–484PubMedCrossRefGoogle Scholar
  27. 27.
    Dzau V, Braunwald E (1991) Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 121(4 Pt 1):1244–1263PubMedCrossRefGoogle Scholar
  28. 28.
    Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP et al (1999) Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 34(6):1281–1286PubMedCrossRefGoogle Scholar
  29. 29.
    Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH (2008) Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med 168(7):721–727PubMedCrossRefGoogle Scholar
  30. 30.
    Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M et al (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the anglo-scandinavian cardiac outcomes trial–lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361(9364):1149–1158PubMedCrossRefGoogle Scholar
  31. 31.
    Juncos LI, Juncos LA, Garcia NH (2012) The antihypertensive actions of statins: modulation by salt intake. Am J Hypertens 25(11):1140–1148PubMedCrossRefGoogle Scholar
  32. 32.
    Schlaich MP, Hering D, Sobotka P, Krum H, Lambert GW, Lambert E et al (2012) Effects of renal denervation on sympathetic activation, blood pressure, and glucose metabolism in patients with resistant hypertension. Front Physiol 3:10PubMedCrossRefGoogle Scholar
  33. 33.
    Lambert GW, Straznicky NE, Lambert EA, Dixon JB, Schlaich MP (2010) Sympathetic nervous activation in obesity and the metabolic syndrome–causes, consequences and therapeutic implications. Pharmacol Ther 126(2):159–172PubMedCrossRefGoogle Scholar
  34. 34.
    Velliquette RA, Ernsberger P (2003) Contrasting metabolic effects of antihypertensive agents. J Pharmacol Exp Ther 307(3):1104–1111PubMedCrossRefGoogle Scholar
  35. 35.
    Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC et al (2011) Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 123(18):1940–1946PubMedCrossRefGoogle Scholar
  36. 36.
    Hall JE, Brands MW, Henegar JR (1999) Mechanisms of hypertension and kidney disease in obesity. Ann N Y Acad Sci 892:91–107PubMedCrossRefGoogle Scholar
  37. 37.
    Briones AM, Cat AN, Callera GE, Yogi A, Burger D, He Y et al (2012) Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 59(5):1069–1078PubMedCrossRefGoogle Scholar
  38. 38.
    Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN (2006) Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 91(1):48–53PubMedCrossRefGoogle Scholar
  39. 39.
    Reckelhoff JF (2007) Polycystic ovary syndrome: androgens and hypertension. Hypertension 49(6):1220–1221PubMedCrossRefGoogle Scholar
  40. 40.
    Chen MJ, Yang WS, Yang JH, Chen CL, Ho HN, Yang YS (2007) Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome. Hypertension 49(6):1442–1447PubMedCrossRefGoogle Scholar
  41. 41.
    Hacihanefioglu B, Somunkiran A, Mahmutoglu I, Sercelik A, Toptani S, Kervancioglu E (2002) Effect of hypertension therapy with the angiotensin-converting enzyme inhibitor lisinopril on hyperandrogenism in women with polycystic ovary syndrome. Fertil Steril 77(3):526–528PubMedCrossRefGoogle Scholar
  42. 42.
    Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al (2007) 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 25(9):1751–1762PubMedCrossRefGoogle Scholar
  43. 43.
    Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S et al (2008) The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens 26(10):1891–1900PubMedCrossRefGoogle Scholar
  44. 44.
    Grossman E, Verdecchia P, Shamiss A, Angeli F, Reboldi G (2011) Diuretic treatment of hypertension. Diabetes Care 34(Suppl 2):S313–S319PubMedCrossRefGoogle Scholar
  45. 45.
    Mancia G, Grassi G, Zanchetti A (2006) New-onset diabetes and antihypertensive drugs. J Hypertens 24(1):3–10PubMedCrossRefGoogle Scholar
  46. 46.
    Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ et al (2009) Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. Blood Press 18(6):308–347PubMedCrossRefGoogle Scholar
  47. 47.
    Destro M, Cagnoni F, Dognini GP, Galimberti V, Taietti C, Cavalleri C et al (2011) Telmisartan: just an antihypertensive agent? A literature review. Expert Opin Pharmacother 12(17):2719–2735PubMedCrossRefGoogle Scholar
  48. 48.
    Cukierman-Yaffe T, Gerstein HC, Anderson C, Zhao F, Sleight P, Hilbrich L et al (2009) Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme. Diabetes Res Clin Pract 83(3):387–393PubMedCrossRefGoogle Scholar
  49. 49.
    Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358(15):1547–1559PubMedCrossRefGoogle Scholar
  50. 50.
    Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I et al (2008) Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372(9644):1174–1183PubMedCrossRefGoogle Scholar
  51. 51.
    Pool JL (1991) Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism. Am Heart J 121(1 Pt 2):251–259PubMedCrossRefGoogle Scholar
  52. 52.
    Yamasaki Y, Shiba Y, Sekiya M, Tsujino T, Hakui N, Kawamori R et al (1994) Selective alpha 1-adrenergic inhibition improves decrease glucose disposal in patients with essential hypertension. J Hum Hypertens 8(8):555–558PubMedGoogle Scholar
  53. 53.
    Haenni A, Lithell H (1999) Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens Suppl 17(3):S29–S35PubMedGoogle Scholar
  54. 54.
    Sowers JR, Whaley-Connell A, Epstein M (2009) Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 150(11):776–783PubMedCrossRefGoogle Scholar
  55. 55.
    Bhalla RC, Toth KF, Tan E, Bhatty RA, Mathias E, Sharma RV (1996) Vascular effects of metformin. Possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat. Am J Hypertens 9(6):570–576PubMedCrossRefGoogle Scholar
  56. 56.
    Zarzuelo MJ, Jimenez R, Galindo P, Sanchez M, Nieto A, Romero M et al (2011) Antihypertensive effects of peroxisome proliferator-activated receptor-beta activation in spontaneously hypertensive rats. Hypertension 58(4):733–743PubMedCrossRefGoogle Scholar
  57. 57.
    Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome–a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 23(5):469–480PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2013

Authors and Affiliations

  1. 1.Institute of Cardiovascular and Medical SciencesUniversity of GlasgowGlasgowUK

Personalised recommendations